Background This systematic review and meta-analysis investigated the diagnostic performance of F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) or PET/computed tomography (PET/CT) for the detection of disease recurrence after curative resection of gastric cancer.
Methods The PubMed and Embase databases, from the earliest available date of indexing through November 30, 2019, were searched for studies evaluating the diagnostic performance of F-18 FDG PET or PET/CT to detect recurrent disease after gastric cancer surgery.
Results Across 17 studies (1,732 patients), the pooled sensitivity for F-18 FDG PET or PET/CT was 0.82 (95% confidence interval [CI], 0.74–0.88) with heterogeneity of I2=76.5 (p<0.001), and the specificity was 0.86 (95% CI, 0.78–0.91) with heterogeneity of I2=94.2 (p<0.001). Likelihood ratio (LR) tests gave an overall positive LR of 6.0 (95% CI, 3.6–9.7) and negative LR of 0.2 (95% CI, 0.14–0.31). The pooled diagnostic odds ratio was 29 (95% CI, 13–63). The summary receiver operating characteristic curve indicates that the area under the curve was 0.91 (95% CI, 0.88–0.93).
Conclusion The current meta-analysis showed good sensitivity and specificity of F-18 FDG PET or PET/CT for detecting recurrent disease after curative resection of gastric cancer despite heterogeneity in ethnicity, recurrence rate, histology, and interpretation method.
Infections involving the heart are becoming increasingly common, and a timely diagnosis of utmost importance, despite its challenges. F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is a recently introduced diagnostic tool in cardiology. This review focuses on the current evidence for the use of FDG PET/CT in the diagnosis of infective endocarditis, cardiac implantable device infection, left ventricular assist device infection, and secondary complications. The author discusses considerations when using FDG PET/CT in routine clinical practice, patient preparation for reducing physiologic myocardial uptake, acquisition of images, and interpretation of PET/CT findings. This review also functions to highlight the need for a standardized acquisition protocol.
Citations
Citations to this article as recorded by
The Role of the 18F-FDG PET/CT in the Management of Patients Suspected of Cardiac Implantable Electronic Devices’ Infection Antonio Rosario Pisani, Dino Rubini, Corinna Altini, Rossella Ruta, Maria Gazzilli, Angela Sardaro, Francesca Iuele, Nicola Maggialetti, Giuseppe Rubini Journal of Personalized Medicine.2024; 14(1): 65. CrossRef
The detection of infectious endocarditis may be enhanced by a repeat FDG-PET while maintaining patients on a ketogenic diet Marine Germaini, Caroline Boursier, François Goehringer, Christine Selton-Suty, Benjamin Lefevre, Véronique Roch, Laetitia Imbert, Marine Claudin, Elodie Chevalier, Pierre-Yves Marie Journal of Nuclear Cardiology.2022; 29(6): 3256. CrossRef
Alzheimer's disease (AD) is a neurodegenerative disorder associated with extracellular plaques, composed of amyloid-beta (Aβ), in the brain. Although the precise mechanism underlying the neurotoxicity of Aβ has not been established, Aβ accumulation is the primary event in a cascade of events that lead to neurofibrillary degeneration and dementia. In particular, the Aβ burden, as assessed by neuroimaging, has proved to be an excellent predictive biomarker. Positron emission tomography, using ligands such as 11C-labeled Pittsburgh Compound B or 18F-labeled tracers, such as 18F-florbetaben, 18F-florbetapir, and 18F-flutemetamol, which bind to Aβ deposits in the brain, has been a valuable technique for visualizing and quantifying the deposition of Aβ throughout the brain in living subjects. Aβ imaging has very high sensitivity for detecting AD pathology. In addition, it can predict the progression from mild cognitive impairment to AD, and contribute to the development of disease-specific therapies.
Citations
Citations to this article as recorded by
Sex modifies effects of imaging and CSF biomarkers on cognitive and functional outcomes: a study of Alzheimer's disease Brian N. Lee, Junwen Wang, Molly A. Hall, Dokyoon Kim, Shana D. Stites, Li Shen Neurobiology of Aging.2024; 133: 67. CrossRef
Current status of PET tracers for the early diagnosis of Alzheimer's disease Yuying Li, Tianqing Liu, Qi Zeng, Mengchao Cui TrAC Trends in Analytical Chemistry.2024; 172: 117546. CrossRef
Cannabidiol and neurodegeneration: From molecular mechanisms to clinical benefits Saurabh Kumar Jha, Vinod Kumar Nelson, Punna Rao Suryadevara, Siva Prasad Panda, Chitikela P. Pullaiah, Mohana Vamsi Nuli, Mehnaz Kamal, Mohd Imran, Saijyothi Ausali, Mosleh Mohammad Abomughaid, Rashi Srivastava, Rahul Deka, Pingal Pritam, Neha Gupta, Har Ageing Research Reviews.2024; 100: 102386. CrossRef
A Study on the Inhibition of AChE Activity by Ethanolic Extract of Tibet Wild Gymnadenia crassinervis and Its Protective and Reparative Effects on Aβ25−35‐Induced Cell Injury Hexingzi Cheng, Anping Li, Pei Yang, Zhengchang Zhong, Hemei Liu, Liangshi Zhang, Qifeng Mo, Christophe Hano Journal of Food Biochemistry.2024;[Epub] CrossRef
Fluorine-18-Labeled Diaryl-azines as Improved β-Amyloid Imaging Tracers: From Bench to First-in-Human Studies Yuying Li, Kaixiang Zhou, Xiaojun Zhang, Hailong Zhao, Xiaoming Wang, Ruilin Dong, Yan Wang, Baian Chen, Xiao-xin Yan, Jiapei Dai, Yanying Sui, Jinming Zhang, Mengchao Cui Journal of Medicinal Chemistry.2023; 66(7): 4603. CrossRef
Design, synthesis and evaluation of fused hybrids with acetylcholinesterase inhibiting and Nrf2 activating functions for Alzheimer's disease Yuanyuan Wang, Baichen Xiong, Hongzhi Lin, Qi Li, Hongyu Yang, Yuting Qiao, Qihang Li, Ziwei Xu, Weiping Lyu, Wei Qu, Wenyuan Liu, Yao Chen, Feng Feng, Haopeng Sun European Journal of Medicinal Chemistry.2022; 244: 114806. CrossRef
Tubulin modifying enzymes as target for the treatment of tau-related diseases Krzysztof Rogowski, Khaled Hached, Carole Crozet, Siem van der Laan Pharmacology & Therapeutics.2021; 218: 107681. CrossRef
Imaging Techniques in Alzheimer’s Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring Wieke M. van Oostveen, Elizabeth C. M. de Lange International Journal of Molecular Sciences.2021; 22(4): 2110. CrossRef
Imaging Techniques as an Aid in the Early Detection of Cardiac Amyloidosis M.F. Santarelli, M. Scipioni, D. Genovesi, A. Giorgetti, P. Marzullo, L. Landini Current Pharmaceutical Design.2021; 27(16): 1878. CrossRef
Protective roles of isoastilbin against Alzheimer's disease via Nrf2‑mediated antioxidation and anti‑apoptosis Hong Yu, Bo Yuan, Qiubo Chu, Chunyue Wang, Hui Bi International Journal of Molecular Medicine.2019;[Epub] CrossRef
Pulmonary artery sarcoma (PAS) is a rare and fatal disease that often mimics chronic thromboembolic pulmonary hypertension (CTEPH); therefore, diagnosis of PAS is often delayed. Herein, a healthy 74-year-old man was presented with a 4-month history of dyspnea. Chest computed tomography showed wall thickening and stenosis in the main pulmonary artery as well as in both proximal pulmonary arteries. In order to differentiate between unusual CTEPH, vasculitis, and PAS, we performed right heart catheterization and pulmonary angiography. The mean pulmonary arterial pressure was 21 mmHg, and there was severe pulmonary artery stenosis. Thrombi on the pulmonary arterial wall lesions were observed in intravascular ultrasound and optical coherence tomography. Furthermore, the patient had a history of deep vein thrombosis. Therefore, we diagnosed unusual CTEPH. After 6 months of rivaroxaban anticoagulation therapy, a chest X-ray revealed a left lower lobe lung mass, and a positron emission tomography later showed hypermetabolic lesions in the main pulmonary artery wall, in both pulmonary arteries walls, in the lung parenchyma, and in the bones. A biopsy of the right proximal humerus lesion revealed undifferentiated intimal sarcoma. Pulmonary sarcoma is rare, but should be considered when differentially diagnosing main pulmonary artery wall thickening and stenosis. A positron emission tomography may aid in this diagnosis.